Clinical trials: Multi-System-Atrophy
Multiple System Atrophy, Parkinsons Disease
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
This phase I double-blind study focuses on the safety and feasibility of implanting autologous peripheral nerve tissue (PNT) into the substantia nigra area of the brain in persons who have been diagnosed with either Parkinson's…
- Trial name
- LEAP (NCT06683365)
- Testing
- Sural Nerve Graft to the Substantia Nigra
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Craig van Horne, MD, PhD
SMA II
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients
The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 2 (SMA 2) patients.
- Trial name
- NCT05901987
- Testing
- GC101
- Where
- 5 sites in China
- Volunteers
- 33 people
- Sponsor
- GeneCradle Inc
Primary Parkinsonism, Secondary Vascular Parkinson Disease
Application of Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms
Based on a prospectively collected data analysis, a new tool, namely CoMDA (Cognition in Movement Disorders Assessment) is developed by merging each item of Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment…
- Conditions
- Primary Parkinsonism, Secondary Vascular Parkinson Disease, Multiple System Atrophy, Supranuclear Palsy, Progressive
- Trial name
- CoMDA-ML-P (NCT04858893)
- Testing
- CoMDA associated with Neural Net 91 classificator
- Where
- Italy
- Volunteers
- 562 people, healthy volunteers welcome
- Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini
Multiple System Atrophy
Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial
A purpose of the present study is to investigate the capability of serum uric acid elevation, safety, and tolerability of inosine 5'-monophosphate in patients with multiple system atrophy with multicenter, randomized, placebo…
- Trial name
- NCT03403309
- Testing
- 1) Inosine 5'-monophosphate
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Yonsei University
Stroke, Ischemic, Stroke Hemorrhagic
Exploring Accessible Beauty for Individuals With Upper Extremity Deficits
The purpose of this study is to investigate the accessibility of beauty products for individuals with upper extremity disabilities.
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic, Stroke (CVA) or TIA, Stroke, Acute
- Trial name
- NCT05945784
- Testing
- Use of Rare Beauty makeup products
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Casa Colina Hospital and Centers for Healthcare
Parkinson's Disease (PD), Multiple System Atrophy
Shanghai Clinical Cohort - Parkinson's Disease (Reserve)
The goal of this observational cohort studyis to establish a high-quality clinical cohort of Parkinson's disease (PD) and multiple system atrophy (MSA) patients in Shanghai, in order to improve early diagnosis, precise subtyping…
- Trial name
- NCT07353463
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Ruijin Hospital
Multiple System Atrophy, Parkinson Variant (Disorder)
DBS and SCS Therapy Improve Motor Function in Multiple System Atrophy With Predominant Parkinsonism
Multiple system atrophy (MSA) is a debilitating and fatal neurodegenerative disorder and symptomatic therapeutic strategies are still limited.The parkinsonian type of MSA (MSA-P) has parkinsonian symptoms as its prominent…
- Trial name
- NCT04617873
- Testing
- Bilateral STN-DBS and T10-T12 SCS
- Where
- China
- Volunteers
- 20 people
- Sponsor
- zhangyuqing
Multiple System Atrophy, Multiple System Atrophy, Cerebellar Variant
Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients
This study will comprise of two phases, an observational phase and a treatment phase. In the observational phase the specific aims are: 1.
- Conditions
- Multiple System Atrophy, Multiple System Atrophy, Cerebellar Variant, Multiple System Atrophy, Parkinson Variant (Disorder), Multiple System Atrophy (MSA) With Orthostatic Hypotension
- Trial name
- NCT04616456
- Testing
- [F-18]PBR06, Verdiperstat
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Brigham and Women's Hospital
Cachexia; Cancer; Sarcopenia
Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics
Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can…
- Trial name
- PRCC-MO (NCT07519837)
- Testing
- Validation of intervention efficacy through enhanced intervention in nutritionally high-risk patients, Standard nutritional intervention was administered as a positive control to validate experimental efficacy.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- China Medical University, China
α-synucleinopathy, Parkinson's Disease (PD)
[18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients
The main objective of this study is to establish a standardized method for [18F] - FD17 PET imaging in α-synucleinopathy patients, and to analyze its physiological distribution in healthy individuals as well as its pathological…
- Conditions
- α-synucleinopathy, Parkinson's Disease (PD), Multiple System Atrophy, Rapid Eye Movement Sleep Behavior Disorder
- Trial name
- NCT06738862
- Testing
- PET
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Multiple System Atrophy
Natural History and Disease Progression Biomarkers of Multiple System Atrophy
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disease characterised by a variable combination of parkinsonism, cerebellar impairment and autonomic dysfunction.
- Trial name
- ASPIRE-MSA (NCT04229173)
- Testing
- MRI acquisition, DAT-SPECT, blood sample, cerebrospinal fluid (optional)
- Where
- 10 sites in France
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Duchenne Muscular Dystrophy (DMD)
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
This is an open-label study to assess the safety, tolerability, efficacy and pharmacokinetics of eteplirsen in patients with early stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
- Trial name
- NCT02420379
- Testing
- eteplirsen
- Where
- 13 sites in United States
- Volunteers
- 33 people
- Sponsor
- Sarepta Therapeutics, Inc.
Myotonic Dystrophy 1
A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
The purpose of this study is to learn about the effects of an investigational medicine, PGN-EDODM1, to see how safe and tolerable multiple administrations of PGN-EDODM1 are for people with myotonic dystrophy type 1 (DM1) compared…
- Trial name
- FREEDOM2-DM1 (NCT06667453)
- Testing
- PGN-EDODM1
- Where
- 12 sites in Canada, New Zealand and 2 more
- Volunteers
- 24 people
- Sponsor
- PepGen Inc
Symptomatic Neurogenic Orthostatic Hypotension, MSA
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
- Trial name
- REDWOOD (NCT03829657)
- Testing
- ampreloxetine
- Where
- 82 sites in United States, Australia and 17 more
- Volunteers
- 203 people
- Sponsor
- Theravance Biopharma
Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Multiple System Atrophy.
- Trial name
- NCT07289477
- Testing
- Human Dopaminergic Progenitor Cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- iRegene Therapeutics Co., Ltd.
Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Motor Neuron Disease Progressive Spinal Muscle Atrophy
Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease
Substantial variability exists in the onset, and rate of degeneration across individuals with Motor Neurone Disease (MND) or Amyotrophic Lateral Sclerosis (ALS).
- Conditions
- Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Motor Neuron Disease Progressive Spinal Muscle Atrophy, Primary Lateral Sclerosis, Multiple Sclerosis
- Trial name
- NCT06320444
- Testing
- 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)
- Where
- Ireland
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Dublin, Trinity College
Multiple System Atrophy
Fluoxetine in Multiple System Atrophy Patients
This is a French national trial, conducted using a double-blind, placebo-controlled, randomised design involving 15 centers and 88 patients of both sexes.
- Trial name
- MSA-Fluox (NCT01146548)
- Testing
- FLUOXETINE
- Where
- 14 sites in France
- Volunteers
- 87 people
- Sponsor
- University Hospital, Toulouse
Duchenne Muscular Dystrophy
Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
The main objective of this study is to evaluate the efficacy of Viltolarsen compared to placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.
- Trial name
- NCT04060199
- Testing
- Viltolarsen
- Where
- 40 sites in United States, Australia and 17 more
- Volunteers
- 77 people
- Sponsor
- NS Pharma, Inc.
Spinal Muscular Atrophy
Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2
To evaluate the safety and efficacy of intravenous onasemnogene abeparvovec-xioi in pre-symptomatic patients with SMA and 2 or 3 copies SMN2
- Trial name
- SPR1NT (NCT03505099)
- Testing
- onasemnogene abeparvovec-xioi
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 30 people
- Sponsor
- Novartis Gene Therapies
REM Sleep Behavior Disorder, Parkinson Disease
North American Prodromal Synucleinopathy Consortium Stage 2
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
- Conditions
- REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies
- Trial name
- NAPS2 (NCT05826457)
- Where
- 9 sites in United States, Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine